{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:07:53Z","timestamp":1784552873258,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jneuroim.2026.578945","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:09:14Z","timestamp":1777561754000},"page":"578945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis"],"prefix":"10.1016","volume":"417","author":[{"given":"Khaled","family":"Zammar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Safan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dareen Jamal","family":"Abushalbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Daromar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Canibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"AlHabil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd A.","family":"Abualrob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jneuroim.2026.578945_bb0010","first-page":"398","article-title":"Treatment outcomes in Nordic NMOSD cohort by AQP4 serostatus","volume":"149","author":"Carlsson","year":"2024","journal-title":"Acta Neurol. Scand."},{"issue":"16","key":"10.1016\/j.jneuroim.2026.578945_bib177","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms22168638","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"22","author":"Chan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10206","key":"10.1016\/j.jneuroim.2026.578945_bb0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jneuroim.2026.578945_bb0030","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578945_bb0035","first-page":"278","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD","volume":"95","author":"H\u00e4u\u00dfler","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578945_bb0040","article-title":"Long-term efficacy and safety of rituximab in the treatment of NMOSD: an Australian cohort study","volume":"10","author":"Hayes","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578945_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9","key":"10.1016\/j.jneuroim.2026.578945_bb0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578945_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02083-1","article-title":"The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt","volume":"21","author":"Kishk","year":"2021","journal-title":"BMC Neurol."},{"issue":"9451","key":"10.1016\/j.jneuroim.2026.578945_bb0065","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578945_bb0070","first-page":"21","article-title":"Therapeutic strategies in neuromyelitis optica spectrum disorders","volume":"23","author":"Levy","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578945_bb0075","first-page":"89","article-title":"Treatment outcomes in seronegative versus seropositive NMOSD: an Indian cohort study","volume":"73","author":"Lotlikar","year":"2025","journal-title":"Neurol. India"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578945_bb0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"issue":"24","key":"10.1016\/j.jneuroim.2026.578945_bb0085","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578945_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103356","article-title":"AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"57","author":"Marignier","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"28","key":"10.1016\/j.jneuroim.2026.578945_bb0095","article-title":"Clinical, radiological and B cell count follow up of Egyptian patients with neuromyelitis optica spectrum disorder on rituximab therapy","volume":"61","author":"Masoud","year":"2025","journal-title":"Egypt J. Neurol. Psychiatry Neurosurg."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.578945_bb0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrn3468","article-title":"Aquaporin water channels in the nervous system","volume":"14","author":"Papadopoulos","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578945_bb0110","first-page":"135","article-title":"Pathogenic mechanisms of autoimmune disorders in the central nervous system: rationale for new therapies","volume":"15","author":"Paul","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578945_bb0115","doi-asserted-by":"crossref","first-page":"578822","DOI":"10.1016\/j.jneuroim.2025.578822","article-title":"Characterizing double seronegative neuromyelitis optica spectrum disorder: a distinct subgroup or part of the continuum?","volume":"411","author":"Piedrabuena","year":"2026","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.578945_bb0120","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578945_bb0125","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.578945_bb0130","first-page":"1080","article-title":"AQP4-IgG-seronegative neuromyelitis optica: a multicentre study","volume":"89","author":"Prain","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578945_bb0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578945_bb9030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.578945_bb0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.578945_bb0150","article-title":"The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: a real-world study from Turkey","volume":"75","author":"Uzunk\u00f6pr\u00fc","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.578945_bb0155","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serological diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2026.578945_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.jneuroim.2026.578945_bb0170","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jneuroim.2026.578945_bb0175","first-page":"e1624","article-title":"Rituximab efficacy in Chinese NMOSD patients by serostatus: results from the TANGO trial","volume":"95","author":"Zhang","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578945_bib176","first-page":"30","article-title":"Clinical features and outcomes of neuromyelitis optica spectrum disorder with negative AQP4-IgG: a systematic review","volume":"328","author":"Zhong","year":"2019","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:56:21Z","timestamp":1784552181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0165572826000937"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578945","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578945"}}